SUBSCRIBE
Search JIM Advanced Search

Journal of Chinese Integrative Medicine ›› 2010, Vol. 8 ›› Issue (4): 312-320.doi: 10.3736/jcim20100403

• Systematic Review • Previous Articles     Next Articles

Xiaochaihu Tang for treatment of chronic hepatitis B: A systematic review of randomized trials

 Xian-kui Qina, Ping Lia, Mei Hanb, Jian-ping Liub,c   

  1. a Outpatient Clinic of People’s Liberation Army Unit 96819,Beijing 100853,China;
    b Center for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China
    c National Research Center in Complementary and Alternative Medicine, University of Troms, Troms N-9037, Norway
  • Received:2009-12-02 Accepted:2010-03-09 Online:2010-04-20 Published:2010-04-15
  • Contact: Jian-ping Liu E-mail:jianping_l@hotmail.com

RichHTML

2

PDF (PC)

182

Like

Background

Xiaochaihu Tang was a compound traditional Chinese herbal medicine recorded in ancient Chinese medical book Shanghanlun, and has been widely used for chronic liver diseases especially in Japan.
Objective

To assess the beneficial effects and safety of Xiaochaihu Tang for chronic hepatitis B (CHB).Search strategy: Electronic and manual searches were conducted and the search ended in November 2009.Inclusion criteria: We included randomized clinical trials testing Xiaochaihu Tang against placebo, non-specific treatment, antivirals, or combined with antivirals against antivirals alone. Data extraction and analysis: Selection of trials for inclusion, assessment of methodological quality by Jadad score, data extraction and data syntheses were conducted according to the Cochrane Hepato-Biliary Group methods．
Results

Sixteen randomized trials (involving 1 601 CHB patients) with various methodological quality were included. One trial published in English had good quality, while other trials published in Chinese were of poor quality. The pooled results showed that Xiaochaihu Tang combined with antiviral drugs was more effective in serum loss of hepatitis B viral markers and in improving liver function compared with antiviral drugs alone. Xiaochaihu Tang was not different from placebo in terms of viral clearance or improving liver function. However, Xiaochaihu Tang was superior to non-specific treatment in liver function improvement. There were no adverse effects reported in the trials regarding Xiaochaihu Tang, but adverse effects were reported in patients treated by interferon, and severe adverse effects occurred in few cases.
Conclusion

Xiaochaihu Tang in this review appears to be effective in improving liver function and clearance of serum hepatitis B viral markers in patients with chronic hepatitis B. However, due to poor methodological quality in the majority of included trials the potential benefits need to be confirmed in rigorous clinical trials following international standards.

Key words: Xiaochaihu Tang, Chronic hepatitis B, Systematic review, Randomized controlled trials

Figure 1

Flow diagram of literature retrieval and selection"

Table 1

Characteristics and methodological quality of included studies"

Study Gender Diagnosis Age Methodology Interventions Control
(Male/Female) (Years) quality
Bo 2006[10] 76/20 Chronic hepatitis B 32.6 Low Xiaochaihu Tang plus interferon-α-2b Interferon-α-2b
Chen 2008[11] 78/42 Chronic hepatitis B fibrosis 38 Low Xiaochaihu Tang plus adefovir dipivoxil Adefovir dipivoxil
He 2008[12] 114/23 Chronic hepatitis B fibrosis 39.8 Low Xiaochaihu tablet plus interferon-α-2b Interferon-α-2b
Hirayama 1989[13] NA Chronic hepatitis B NA High Xiaochaihu Tang Placebo
Li 2001[14] 80/30 Chronic hepatitis B fibrosis 30—60 Low Xiaochaihu Tang plus interferon-γ Interferon-γ
Li 2009[15] 45/23 Chronic hepatitis B 32.1 Low Xiaochaihu Tang plus lamivudine Lamivudine
Miao 2001[16] 28/22 Chronic hepatitis B NA Low Xiaochaihu Tang plus Danshen Injection Essentiale forte
Shi 2006[17] 50/26 Chronic hepatitis B 15—40 Low Xiaochaihu Tang plus interferon Interferon
Sun 2003[18] 62/32 Chronic hepatitis B fibrosis 43.6 Low Xiaochaihu Tang plus oxymatrine injection Vitamins
Wang 1992[19] NA Chronic hepatitis B NA Low Xiaochaihu Tang plus autologous LAK cell infusion Autologous LAK cell infusion
Wu 1994[20] NA Chronic hepatitis B NA Low Xiaochaihu Tang plus autologous LAK cell infusion Autologous LAK cell infusion
Wu 2009[21] 85/56 Chronic hepatitis B cirrhosis 32—80 Low Xiaochaihu Tang Transaminase-lowering drug
Xiong 2003[22] 65/21 Chronic hepatitis B fibrosis 39.7 Low Xiaochaihu Tang plus interferon-α Interferon-α
Yu 2000[23] NA Chronic hepatitis B 15—65 Low Xiaochaihu Tang plus ribavirin Ribavirin
Zhang 1998[24] 56/21 Chronic hepatitis B 18—56 Low Xiaochaihu Tang Inosine, vitamins C
Zhang 2008[25] 58/16 Chronic hepatitis B 41 Low Xiaochaihu Tang plus interferon-α-2b Interferon-α-2b
Study Duration of Follow-up Outcome measures
treatment (weeks) (months)
Bo 2006[10] 24 0 Symptoms, HBsAg, HBeAg, HBV-DNA, liver function, side effects
Chen 2008[11] 52 0 HBeAg, HBV-DNA, liver function, side effects
He 2008[12] 24 0 Liver fibrosis, liver function
Hirayama 1989[13] 12 3 HBsAg, HBeAg, anti-HBe, liver function, side effects
Li 2001[14] 12 0 Liver function, liver fibrosis
Li 2009[15] 12 0 Liver function, HBeAg, HBV-DNA
Miao 2001[16] 12 0 Symptoms, liver function, HBeAg, HBV-DNA
Shi 2006[17] 16 0 Liver function, HBsAg, HBeAg , HBV-DNA
Sun 2003[18] 24 0 Liver function, liver fibrosis, side effects
Wang 1992[19] 6 6 Liver function, HBeAg, anti-HBe, HBV-DNA
Wu 1994[20] 6 0 HBsAg, HBeAg, HBV-DNA, side effects
Wu 2009[21] 24 36 Symptoms, liver function, side effects
Xiong 2003[22] 12 0 Symptoms, liver function, liver fibrosis
Yu 2000[23] 12 9 Symptoms, liver function, HBeAg, HBV-DNA, side effects
Zhang 1998[24] 16 12 Symptoms, liver function, side effects
Zhang 2008[25] 24 0 Symptoms, liver function, HBeAg, HBV-DNA, side effects

Table 2

Analysis of antiviral response"

Antiviral response Intervention
(n/N)		 Control
(n/N）		 RR
[95% CI]		 P value
Loss of serum HBsAg
Xiaochaihu Tang compared with placebo
Xiaochaihu Tang vs placebo 1 52/116 47/106 1.01 [0.75, 1.36] 0.94
Xiaochaihu Tang plus antivirals compared with antivirals
Xiaochaihu Tang plus interferon-α-2b vs interferon-α-2b 1 7/50 4/46 1.61 [0.50, 5.14] 0.42
Xiaochaihu Tang plus interferon vs interferon 1 1/46 0/30 1.98 [0.08, 47.03] 0.67
Meta-analysis 2 8/96 4/76 1.66 [0.56, 4.94] 0.36
Loss of serum HBeAg
Xiaochaihu Tang compared with placebo
Xiaochaihu Tang vs placebo 1 33/116 32/106 0.94 [0.63, 1.42] 0.78
Xiaochaihu Tang compared with non-specific treatment
Xiaochaihu Tang plus Danshen Injection vs essentiale forte 1 16/30 2/20 5.33 [1.37, 20.71] 0.02
Xiaochaihu Tang plus immunotherapy compared with immunotherapy
Xiaochaihu Tang plus autologous LAK cell infusion vs autologous
LAK cell infusion		 2 43/65 38/75 1.29 [0.97, 1.71] 0.08
Xiaochaihu Tang plus antivirals compared with antivirals
Xiaochaihu Tang plus interferon-α-2b vs interferon-α-2b 1 29/50 17/46 1.57 [1.01, 2.45] 0.05
Xiaochaihu Tang plus adefovir dipivoxil vs adefovir dipivoxil 1 18/60 12/60 1.50 [0.79, 2.84] 0.21
Xiaochaihu Tang plus lamivudine vs lamivudine 1 19/34 10/34 1.90 [1.04, 3.46] 0.04
Xiaochaihu Tang plus interferon vs interferon 1 18/46 9/30 1.30 [0.68, 2.51] 0.43
Xiaochaihu Tang plus ribavirin vs ribavirin 1 31/57 46/55 0.65 [0.50, 0.85] 0.001
Xiaochaihu Tang plus interferon-α-2b vs interferon-α-2b 1 21/40 14/45 1.69 [1.00, 2.85] 0.05
Meta-analysis 6 136/287 71/270 1.74 [1.38, 2.19] <0.000 0
Loss of serum HBV-DNA
Xiaochaihu Tang compared with non-specific treatment
Xiaochaihu Tang plus Danshen Injection vs essentiale forte 1 8/18 2/11 2.44 [0.63, 9.48] 0.20
Xiaochaihu Tang plus immunotherapy compared with immunotherapy
Xiaochaihu Tang plus autologous LAK cell infusion vs autologous
LAK cell infusion		 2 43/65 36/75 1.36 [1.01, 1.82] 0.04
Xiaochaihu Tang plus antivirals compared with antivirals
Xiaochaihu Tang plus interferon-α-2b vs interferon-α-2b 2 52/90 35/91 1.49 [1.09, 2.04] 0.01
Xiaochaihu Tang plus adefovir dipivoxil vs adefovir dipivoxil 1 23/60 18/60 1.28 [0.77, 2.11] 0.34
Xiaochaihu Tang plus interferon vs interferon 1 17/46 7/30 1.58 [0.75, 3.35] 0.23
Xiaochaihu Tang plus ribavirin vs ribavirin 1 16/57 4/55 3.86 [1.38, 10.82] 0.01
Xiaochaihu Tang plus lamivudine vs lamivudine 1 29/34 26/34 1.12 [0.88, 1.41] 0.36
Meta-analysis 6 137/287 90/270 1.46 [1.20, 1.77] 0.000 1

Table 3

Analysis of liver function parameters"

Liver function parameter MD [95% CI] P value
Lower ALT level (U/L)
Xiaochaihu Tang compared with placebo
Xiaochaihu Tang vs placebo 1 –2.00 [–41.34, 37.34] 0.92
Xiaochaihu Tang compared with non-specific treatment
Xiaochaihu Tang plus Danshen Injection vs essentiale forte 1 –1.04 [–11.26, 9.18] 0.84
Xiaochaihu Tang plus oxymatrine injection vs vitamins 1 –21.32 [–40.87, –1.77] 0.03
Meta-analysis [FEM] 2 –5.40 [–14.46, 3.66] 0.33
Meta-analysis [REM] 2 –9.40 [–28.96, 10.17] 0.35
Xiaochaihu Tang compared with transaminase-lowering drug
Xiaochaihu Tang vs transaminase-lowering drug 1 –12.60 [–13.31, –11.89] < 0.000 01
Xiaochaihu Tang plus antivirals compared with antivirals
Xiaochaihu Tang plus interferon-α-2b vs interferon-α-2b 2 –23.66 [–33.85, –13.47] <0.000 01
Xiaochaihu Tang plus adefovir dipivoxil vs adefovir dipivoxil 1 –32.00 [–40.00, –24.00] <0.000 01
Xiaochaihu tables plus interferon-α-2b vs interferon-α-2b 1 –3.85 [–12.24, 4.54] 0.37
Xiaochaihu Tang plus interferon-γ vs interferon-γ 1 –19.68 [–38.04, –1.32] 0.04
Xiaochaihu Tang plus lamivudine vs lamivudine 1 –1.10 [–9.68, 7.48] 0.80
Xiaochaihu Tang plus interferon vs interferon 1 –46.00 [–68.73, –23.27] <0.000 1
Xiaochaihu Tang plus interferon-α vs interferon-α 1 –91.75 [–111.69, –71.81] <0.000 01
Meta-analysis [FEM] 8 –19.45 [–23.51, 15.38] <0.000 01
Meta-analysis [REM] 8 –29.18 [–45.30, –13.07] 0.000 4
Lower AST level (U/L)
Xiaochaihu Tang compared with placebo
Xiaochaihu Tang vs placebo 1 –5.00 [–27.64, 17.64] 0.67
Xiaochaihu Tang compared with non-specific treatment
Xiaochaihu Tang plus Danshen Injection vs essentiale forte 1 0.99 [–7.30, 9.28] 0.81
Xiaochaihu Tang plus oxymatrine injection vs vitamins 1 –25.58 [–47.67, –3.49] 0.02
Meta-analysis [FEM] 2 –2.29 [–10.05,5.47] 0.56
Meta-analysis [REM] 2 –10.24 [–35.79,15.48] 0.44
Xiaochaihu Tang compared with transaminase-lowering drug
Xiaochaihu Tang vs transaminase-lowering drug 1 –10.30 [–11.09,–9.51] <0.000 01
Xiaochaihu Tang plus antivirals compared with antivirals
Xiaochaihu Tang plus adefovir dipivoxil vs adefovir dipivoxil 1 –28.00 [–35.79, –20.21] <0.000 01
Xiaochaihu Tablets plus interferon-α-2b vs interferon-α-2b 1 7.09 [–0.29, 14.47] 0.06
Xiaochaihu Tang plus lamivudine vs lamivudine 1 –33.80 [–44.98, –22.62] <0.000 01
Xiaochaihu Tang plus interferon vs interferon 1 –45.60 [–64.99, –26.21] <0.000 01
Xiaochaihu Tang plus interferon-α vs interferon-α 1 –25.01 [–45.26, –4.76] 0.02
Xiaochaihu Tang plus interferon-α-2b vs interferon-α-2b 1 –53.90 [–68.23, –39.57] <0.000 01
Meta-analysis [FEM] 6 –19.81 [–24.16,–15.46] <0.000 01
Meta-analysis [REM] 6 –29.34 [–49.17, –9.52] 0.004
Lower TBIL level (U/L)
Xiaochaihu Tang compared with non-specific treatment
Xiaochaihu Tang plus oxymatrine injection vs vitamins 1 –6.28 [–12.62, 0.06] 0.05
Xiaochaihu Tang plus antivirals compared with antivirals
Xiaochaihu Tang plus adefovir dipivoxil vs adefovir dipivoxil 1 –5.00 [–8.80, –1.20] 0.010
Xiaochaihu Tang plus interferon-γ vs interferon-γ 1 –3.25 [–4.20, –2.30] <0.000 01
Xiaochaihu Tang plus lamivudine vs lamivudine 1 –0.50 [–3.81, 2.81] 0.77
Xiaochaihu Tang plus interferon-α vs interferon-α 1 –4.32 [–10.38, 1.74] 0.16
Meta-analysis 4 –3.17 [–4.05, –2.30] <0.000 01
[1] Huang HZ, Wang RX, Zhou XL . Advance in application of drugs for hepatitis B and strategy for research and development[J]. Yi Yao Dao Bao, 2008,27(4):397-400
黄海舟, 王荣先, 周晓靓 . 乙肝治疗药物应用进展与研究开发策略[J]. 医药导报, 2008,27(4):397-400
[2] Xu W, Su LQ, Li HJ . Research advances and clinical evaluation of drugs for hepatitis B[J]. Zhongguo Yi Yuan Yao Xue Za Zhi, 2008,28(9):737-739
徐巍, 苏乐群, 李宏建 . 乙肝治疗药物的研究进展及临床评价[J]. 中国医院药学杂志, 2008,28(9):737-739
[3] Run J, Xie W, Lin YH, Feng X, Wang BB, Xiao J, Ou WN, Wang YB, Cheng J . Effect of adeforvir dipivoxil on the frequency of HBcAg-specific cytotoxic T cells in patients with chronic hepatitis B[J]. Shi Jie Hua Ren Xiao Hua Za Zhi, 2009,17(19):1996-1999
闰杰, 谢雯, 蔺亚辉, 冯鑫, 王蓓蓓, 肖江, 欧蔚妮, 王艳斌, 成军 . 阿德福韦酯对慢性乙肝患者外周血HBcAg特异性CTL的影响[J]. 世界华人消化杂志, 2009,17(19):1996-1999
[4] Wang LF, Han CN, Liu YF . Thoughts on the treatment of chronic hepatitis B[J]. Hunan Zhong Yi Za Zhi, 2008,24(6):80-81
王礼凤, 韩翠宁, 刘养凤 . 关于慢性乙肝治疗的思考[J]. 湖南中医杂志, 2008,24(6):80-81
[5] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL . Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B[J]. N Engl J Med, 2003,348(12):800-807
doi: 10.1056/NEJMoa021812
[6] Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ , McQuay HJ.Assessing the quality of reports of randomized clinical trials: is blinding necessary?[J]. Control Clin Trials, 1996,17:1-12
doi: 10.1016/0197-2456(95)00134-4
[7] Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP . Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?[J]. Lancet, 1998,9(2):609-613
[8] Higgins JPT, Green S . Cochrane handbook for systematic reviews of interventions, version 5.0.1 [updated September 2008.]
[9] Schulz KF, Chalmers I, Hayes RJ, Altman DG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials[J]. JAMA, 1995,273(5):408-412
doi: 10.1001/jama.1995.03520290060030
[10] Bo QL, Du WW . Observation on effect of interferon combined with Xiaochaihu Tang for treatment of 50 patients with chronic hepatitis B[J]. Shandong Yi Yao, 2006,46(8):82-83
薄其兰, 杜雯雯 . 干扰素联合小柴胡汤治疗慢性乙肝50例疗效观察[J]. 山东医药, 2006,46(8):82-83
[11] Chen XT, Wen SX, Huang JL, Gu H, Yan WX, Huang CY . Study on adeforvir dipivoxil combined with Xiaochaihu Tang for treatment of chronic hepatitis B-induced liver fibrosis[J]. Ji Ceng Yi Xue Lun Tan, 2008,12(9):786-788
陈小桃, 文顺喜, 黄坚灵, 古辉, 严伟兴, 黄彩云 . 阿德福韦酯联合小柴胡汤治疗乙肝肝纤维化的研究[J]. 基层医学论坛, 2008,12(9):786-788
[12] He BF, Zhou JK, Shen HJ . Clinical study of Xiaochaihu Tablet in combination with interferon in the treatment of chronic hepatitis B fibrosis[J]. Zhongguo Zhong Xi Yi Jie He Xiao Hua Za Zhi, 2008,16(6):384-387
何炳福, 周建康, 沈华江 . 小柴胡片联合干扰素治疗慢性乙肝肝纤维化的临床研究[J]. 中国中西医结合消化杂志, 2008,16(6):384-387
[14] 李峥, 廖红华, 吴梅江, 林志红 . γ干扰素与小柴胡汤联合抗肝纤维化的研究[J]. 中西医结合肝病杂志, 2001,11(S1):95
Hirayama C, Okumura M, Tanikawa K, Yano M, Mizuta M, Ogawa N . A multicenter randomized controlled clinical trial of Shosaiko-to in chronic active hepatitis[J]. Gastroenterol Jpn, 1989,24(6):715-719
[15] Li ZQ . Observation of Xiaochaihu Tang combined with lamivudine for treatment of chronic hepatitis B[J]. Hebei Zhong Yi, 2009,31(5):709-710
李正秋 . 小柴胡汤联合拉米夫定治疗慢性乙型病毒性肝炎的临床观察[J]. 河北中医, 2009,31(5):709-710
[16] Miao WF, Li HY . Modified Xiaochaihu Tang combined with Danshen Injection for treatment of 30 patients with chronic hepatitis B[J]. Shi Yong Zhong Yi Yao Za Zhi, 2001,17(6):3-4
缪伟峰, 李惠义 . 加减小柴胡汤合丹参注射液治疗慢性乙型病毒性肝炎30例观察[J]. 实用中医药杂志, 2001,17(6):3-4
[17] Shi WY, Zhang JQ . Interferon combined with Xiaochaihu Tang for treatment of chronic hepatitis B[J]. Hubei Zhong Yi Za Zhi, 2006,28(12):35
史文英, 张军勤 . 干扰素联合小柴胡汤治疗慢性乙型病毒性肝炎[J]. 湖北中医杂志, 2006,28(12):35
[18] Sun WH, Song MQ, Liu ZJ . Xiaochaihu Tang combined with matrine injection for treatment of 64 patients with chronic hepatitis B[J]. Zhong Xi Yi Jie He Gan Bing Za Zhi, 2003,13(1):41-42
孙维会, 宋明全, 刘中景 . 小柴胡汤联合苦参素注射液治疗肝炎肝纤维化64例[J]. 中西医结合肝病杂志, 2003,13(1):41-42
[19] Wang CG, Li XH, Huang SX, Li SQ, Huang JQ, Zhou JY . Autologous LAK cell infusion combined with Xiaochaihu Tang or IL-Ⅱ for treatment of 173 patients with chronic hepatitis B[J]. Lin Chuang Gan Dan Bing Za Zhi, 1992,8(4):191-194
王崇国, 李旭红, 黄水仙, 李树青, 黄金泉, 周佳彦 . 自体LAK细胞回输加小柴胡汤或白细胞介素Ⅱ治疗慢性乙肝173例疗效分析[J]. 临床肝胆病杂志, 1992,8(4):191-194
[20] Wu W, Li YH, Peng ZJ, Luo WJ . Autologous LAK cell infusion combined with Xiaochaihu Tang for treatment of 32 patients with chronic hepatitis B[J]. Zhong Xi Yi Jie He Gan Bing Za Zhi, 1994,4(4):31
吴玮, 李彦恒, 彭真基, 罗维礁 . 自体LAK细胞回输加小柴胡汤治疗慢性乙肝32例[J]. 中西医结合肝病杂志, 1994,4(4):31
[21] Wu QQ . Clinical observation of Xiaochaihu Tang for treatment of 69 patients with hepatitis B-induced liver cirrhosis[J]. Zhejiang Zhong Yi Yao Da Xue Xue Bao, 2009,33(4):517-518
吴俏青 . 小柴胡汤化裁治疗乙肝肝硬化69例临床观察[J]. 浙江中医药大学学报, 2009,33(4):517-518
[22] Xiong F, Sun J, Xiong W . Clinical observation of interferon combined with Xiaochaihu Tang for treatment of liver fibrosis[J]. Hubei Zhong Yi Za Zhi, 2003,25(10):10-11
熊凡, 孙静, 熊伟 . 干扰素联合小柴胡汤治疗肝纤维化的临床观察[J]. 湖北中医杂志, 2003,25(10):10-11
[23] Yu AQ, Wang KQ, Zhang WD, Li CY, Shen LM, Zhang W . Modified Xiaochaihu Tang combined with ribavirin for treatment of chronic hepatitis B[J]. Zhejiang Zhong Xi Yi Jie He Za Zhi, 2000,10(3):133-135
余安清, 王克奇, 张文鼎, 李春勇, 沈黎明, 张文 . 加味小柴胡汤与病毒唑联用治疗慢性乙肝[J]. 浙江中西医结合杂志, 2000,10(3):133-135
[24] Zhang XH, Guo XZ . The effect of Xiaochaihu Tang on HBVM and ALT of chronic hepatitis B[J]. Zhongguo Zhong Yi Yao Xin Xi Za Zhi, 1998,5(8):36
张学海, 郭秀珠 . 小柴胡汤对慢乙肝HBVM及ALT的影响[J]. 中国中医药信息杂志, 1998,5(8):36
[25] Zhang YC, Liu ZJ . The clinical observation of Jiaweixiaochaihu combined with interferon treatment of chronic hepatitis B HbeAg positive preliminary[J]. Zhongguo Shi Yong Yi Yao, 2008,3(33):50-51
张迎春, 刘中景 . 加味小柴胡汤联合干扰素治疗HBeAg阳性慢性乙肝疗效初步临床观察[J]. 中国实用医药, 2008,3(33):50-51
[26] Zhang YP, Jiang KP . Xiaochaihu granules combined with glycyrrhizin for treatment of 44 patients with chronic hepatitis B[J]. Shi Yong Yi Xue Za Zhi, 2001,17(8):778-779
张玉萍, 蒋开平 . 小柴胡冲剂合甘利欣治疗慢性乙肝44例[J]. 实用医学杂志, 2001,17(8):778-779
[27] Jia KM, Peng XJ, Deng YL, Wang GL, Zhai HS, Cong YH, Chen NL . A study of Xiaochaihu Tang for treatment of chronic hepatitis B[J]. Jie Fang Jun Yi Xue Za Zhi, 1990,15(2):95-97
贾克明, 彭晓君, 邓燕林, 王桂林, 翟岵生, 丛云辉, 陈乃玲 . 小柴胡汤治疗慢性活动型肝炎的研究[J]. 解放军医学杂志, 1990,15(2):95-97
[28] Sun XN, Sun JB . Xiaochaihu Tang combined with glycyrrhizin injection for treatment of 60 patients with hepatitis-induced liver fibrosis[J]. Zhongguo Zhong Yi Yao Xin Xi Za Zhi, 2004,11(6):534-535
孙晓娜, 孙俊波 . 小柴胡汤联合甘利欣注射液治疗肝炎肝纤维化60例[J]. 中国中医药信息杂志, 2004,11(6):534-535
[29] Sun Y . Xiaochaihu Tang for treatment of 32 patients with chronic hepatitis B[J]. Heilongjiang Zhong Yi Yao, 2005,17(3):34
孙阳 . 小柴胡汤治疗慢性乙型病毒性肝炎32例[J]. 黑龙江中医药, 2005,17(3):34
[30] Tu YS . Modified Xiaochaihu Tang for treatment of 66 patients with chronic active hepatitis B[J]. Hunan Zhong Yi Yao Dao Bao, 1996,2(4):11-12
涂瑶生 . 加味小柴胡汤治疗慢性活动性乙肝66例[J]. 湖南中医药导报, 1996,2(4):11-12
[31] Xie SD . Xiaochaihu Tang or combined with hepatitis B vaccine for treatment of 176 patients with chronic hepatitis B[J]. Jiangsu Zhong Yi, 1995,16(9):7
谢士达 . 小柴胡汤或合用乙肝疫苗治疗慢性乙肝176例[J]. 江苏中医, 1995,16(9):7
[32] Yang YN . Xiaochaihu Tang for treatment of 60 patients with chronic hepatitis B[J]. Neimenggu Zhong Yi Yao, 2009,28(6):38-39
杨艳娜 . 小柴胡汤治疗慢性乙肝60例[J]. 内蒙古中医药, 2009,28(6):38-39
[33] Liu JP . Report of randomized controlled clinical trials[J]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2005,25(4):297-298
刘建平 . 随机对照临床试验的报告[J]. 中国中西医结合杂志, 2005,25(4):297-298
[1] Ming-min Xu, Pei Guo, Qing-yu Ma, Xuan Zhou, Yu-long Wei, Lu Wang, Yue Chen, Yu Guo. Can acupuncture enhance therapeutic effectiveness of antidepressants and reduce adverse drug reactions in patients with depression? A systematic review and meta-analysis. Journal of Integrative Medicine, 2022, 20(4): 305-320.
[2] Ting-ting Lu, Cun-cun Lu, Mei-xuan Li, Li-xin Ke, Hui Cai, Ke-hu Yang. Reporting and methodological quality of meta-analyses of acupuncture for patients with migraine: A methodological investigation with evidence map. Journal of Integrative Medicine, 2022, 20(3): 213-220.
[3] Witoo Dilokthornsakul, Ramanya Kosiyaporn, Rattanamanee Wuttipongwaragon, Piyameth Dilokthornsakul. Potential effects of propolis and honey in COVID-19 prevention and treatment: A systematic review of in silico and clinical studies. Journal of Integrative Medicine, 2022, 20(2): 114-125.
[4] Jun-peng Yao, Li-ping Chen, Xian-jun Xiao, Ting-hui Hou, Si-yuan Zhou, Ming-min Xu, Kai Wang, Yu-jun Hou, Lin Zhang, Ying Li. Effectiveness and safety of acupuncture for treating functional constipation: An overview of systematic reviews. Journal of Integrative Medicine, 2022, 20(1): 13-25.
[5] Yi Yuan, Rui-Ting Wang, Jun Xia, Hui-Juan Cao. Interventions for preventing influenza: an overview of Cochrane systematic reviews and a Bayesian network meta-analysis. Journal of Integrative Medicine, 2021, 19(6): 503-514.
[6] Meng-zhu Zhao, Chen Zhao, Shuang-shuang Tu, Xu-xu Wei, Hong-cai Shang. Evaluating the methodology of studies conducted during the global COVID-19 pandemic: A systematic review of randomized controlled trials. Journal of Integrative Medicine, 2021, 19(4): 317-326.
[7] Liang Dai, Ka Kei Chan, Jian-chun Mao, Yu Tian, Jun-hua Gu, Jun Zhou, Linda L.D. Zhong. Modified Zhibai Dihuang pill, a traditional Chinese medicine formula, on steroid withdrawal in systemic lupus erythematosus: A systematic review and meta-analysis. Journal of Integrative Medicine, 2020, 18(6): 478-491.
[8] Arthur Yin Fan, Sherman Gu, Sarah Faggert Alemi, Research Group for Evidence-based Chinese Medicine. Chinese herbal medicine for COVID-19: Current evidence with systematic review and meta-analysis. Journal of Integrative Medicine, 2020, 18(5): 385-394.
[9] Xian-jun Xiao, Lei-xiao Zhang, Yun-zhou Shi, Jun-peng Yao, Wei Cao, Ying Liu, Zi-hao Zou, Si-yuan Zhou, Ming-ling Chen, Chun-xiao Li, Qian-hua Zheng, Ying Li. Cupping therapy for patients with chronic urticaria: A systematic review and meta-analysis. Journal of Integrative Medicine, 2020, 18(4): 303-312.
[10] Dong-dong Yu, Liang-zhen You, Wan-qiu Huang, Hui Cao, Fan-jing Wang, Xiu-qin Tang, Zhao-hui Fang, Guo-ming Shen, Yu-xiang Guan. Effects of traditional Chinese exercises on blood glucose and hemoglobin A1c levels in patients with prediabetes: A systematic review and meta-analysis. Journal of Integrative Medicine, 2020, 18(4): 292-302.
[11] Jia Xu, Fu-qing Zhang, Jian Pei, Jun Ji . Acupuncture for migraine without aura: A systematic review and meta-analysis. Journal of Integrative Medicine, 2018, 16(5): 312-321.
[12] Maria T.Chao, AlexandraChang, SanjayReddy, James D.Harrison, JosephAcquah, MiriaToveg, TrilceSantana, Frederick M.Hecht. Adjunctive acupuncture for pain and symptom management in the inpatient setting: Protocol for a pilot hybrid effectiveness-implementation study. Journal of Integrative Medicine, 2016, 14(3): 228-238.
[13] Nouran A. Aleyeidi, Khaled S. Aseri, Shadia M. Matbouli, Albaraa A. Sulaiamani, Sumayyah A. Kobeisy. Effects of wet-cupping on blood pressure in hypertensive patients: A randomized controlled trial. Journal of Integrative Medicine, 2015, 13(6): 391-399.
[14] Sung Min Lim, Sook-Hyun Lee. Effectiveness of bee venom acupuncture in alleviating post-stroke shoulder pain: A systematic review and meta-analysis. Journal of Integrative Medicine, 2015, 13(4): 241-247.
[15] Heather Ann Hausenblas, Kacey Heekin, Heather Lee Mutchie, Stephen Antonb. A systematic review of randomized controlled trials examining the effectiveness of saffron (Crocus sativus L.) on psychological and behavioral outcomes. Journal of Integrative Medicine, 2015, 13(4): 231-240.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] Wei-xiong Liang. Problems-solving strategies in clinical treatment guideline for traditional Chinese medicine and integrative medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 1-4
[2] Zhao-guo Li. Discussion on English translation of commonly used sentences in traditional Chinese medicine: part one. Journal of Chinese Integrative Medicine, 2008, 6(1): 107-110
[3] Jun Hu, Jian-ping Liu. Non-invasive physical treatments for chronic/recurrent headache. Journal of Chinese Integrative Medicine, 2008, 6(1): 31
[4] Xue-mei Liu, Qi-fu Huang, Yun-ling Zhang, Jin-li Lou, Hong-sheng Liu, Hong Zheng. Effects of Tribulus terrestris L. saponion on apoptosis of cortical neurons induced by hypoxia-reoxygenation in rats. Journal of Chinese Integrative Medicine, 2008, 6(1): 45-50
[5] . Uniform requirements for manuscripts submitted to biomedical journals: Writing and editing for biomedical publication (Chinese version, part two). Journal of Chinese Integrative Medicine, 2010, 8(11): 1001-1005
[6] Daniel Weber, Janelle M Wheat, Geoffrey M Currie. Inflammation and cancer: Tumor initiation, progression and metastasis,and Chinese botanical medicines. Journal of Chinese Integrative Medicine, 2010, 8(11): 1006-1013
[7] Hong Liu , Guo-liang Zhang, Li Shen , Zhen Zeng, Bao-luo Zhou, Cheng-hai Liu, Guang Nie . Application and evaluation of a pseudotyped virus assay for screening herbs for anti-H5Nl avian influenza virus. Journal of Chinese Integrative Medicine, 2010, 8(11): 1036-1040
[8] Zhao-guo Li . A discussion of English translation of 1995 and 1997 Chinese National Standards of Traditional Chinese Medical Terminologies for Clinical Diagnosis and Treatment. Journal of Chinese Integrative Medicine, 2010, 8(11): 1090-1096
[9] Rui Jin, Bing Zhang. A complexity analysis of Chinese herbal property theory: the multiple formations of herbal property (Part 1). Journal of Chinese Integrative Medicine, 2012, 10(11): 1198-1205
[10] Hui-min Liu, Xian-bo Wang, Yu-juan Chang, Li-li Gu. Systematic review and meta-analysis of randomized controlled trials of integrative medicine therapy for treatment of chronic severe hepatitis. Journal of Chinese Integrative Medicine, 2012, 10(11): 1211-1228
Journal of Integrative Medicine, ISSN: 2095-4964 CN 31-2083/R
Copyright © Journal of Integrative Medicine
Powered by Beijing Magtech Co. Ltd
沪公网安备31010602003416号      沪ICP备18017633号-3